ArticleEuropean journal of medical research2025
Unraveling the causal role of TGF-βRII in osteoporosis and the potential of its associated differential genes as novel targets.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role and mechanisms of bone microenvironment regulators in osteoporosis: novel intervention strategies for addressing the challenges of aging.Frontiers in endocrinology · 2026Review
- Immune-Guided Bone Healing: The Role of Osteoimmunity in Tissue Engineering Approaches.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis (OP) is a common disorder associated with reduced density of the bones, increasing the likelihood of fractures and deformities. The global incidence of OP is rising rapidly due to aging populations and lifestyle changes, affecting not only older adults but, increasingly, younger and middle-aged individuals. The long-term care and rehabilitation required for OP-induced fractures and complications impose significant economic burdens on both individuals and society, as well as reducing their quality of life.
methodsRecent studies have demonstrated an association between transforming growth factor-beta type II receptor (TGF-βRII) and OP through analysis of gene expression data sets and Mendelian randomization, suggesting potential causal relationships. Differentially expressed genes (DEGs) were identified between mesenchymal stem cells (MSCs) from OP patients and healthy controls in the GEO database, and their functions were analyzed. The relationships between the identified genes and their effects on immune cells were examined in terms of ceRNAs and immune infiltration. Single-cell RNA-seq data of OP patients in GSE147287 was used to investigate effects on MSC differentiation from DEGs, and gene expression data were verified using RT-qPCR.
resultsThe molecular pathways underlying OP were explored by focusing on the role of MSCs and TGF-β signaling, identifying a significant causal link between TGFBRII and OP. DEGs associated with the TGF-β pathway included ID2, ID4, LRRC32, and EMP3, which are closely related to bone homeostasis and the differentiation of bone marrow MSCs. In addition, analysis of immune infiltration showed the involvement of these genes in various immune cells, and potential non-coding RNA targeting ID2, ID4, and LRRC32 were investigated using ceRNA networks. Single-cell sequencing demonstrated the expression of ID2, ID4, LRRC32, and EMP3 in bone marrow MSCs and their effects on MSC differentiation.
conclusionsTGFBRII was found to be causally associated with OP. ID2, ID4, LRRC32, and EMP3 affect the differentiation and osteogenic function of bone marrow MSCs through the TGF-β pathway, suggesting the potential of ID2, ID4, LRRC32, and EMP3 as therapeutic targets for treating osteoporosis. In summary, targeting of ID2, ID4, LRRC32, and EMP3 holds significant promise for the treatment of OP, providing new targets and strategies, and precise treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.